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OBJECTIVE — The efﬁcacy and safety of adding liraglutide (a glucagon-like peptide-1 re-
ceptor agonist) to metformin were compared with addition of placebo or glimepiride to met-
formin in subjects previously treated with oral antidiabetes (OAD) therapy.
RESEARCH DESIGN AND METHODS — In this 26-week, double-blind, double-
dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly
assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutane-
ously), to placebo, or to glimepiride (4 mg once daily). All treatments were in combination
therapy with metformin (1g twice daily). Enrolled subjects (aged 25–79 years) had type 2
diabetes,A1Cof7–11%(previousOADmonotherapyfor3months)or7–10%(previousOAD
combination therapy for 3 months), and BMI 40 kg/m
2.
RESULTS — A1C values were signiﬁcantly reduced in all liraglutide groups versus the pla-
cebogroup(P0.0001)withmeandecreasesof1.0%for1.8mgliraglutide,1.2mgliraglutide,
and glimepiride and 0.7% for 0.6 mg liraglutide and an increase of 0.1% for placebo. Body
weight decreased in all liraglutide groups (1.8–2.8 kg) compared with an increase in the
glimepiride group (1.0 kg; P  0.0001). The incidence of minor hypoglycemia with liraglutide
(3%) was comparable to that with placebo but less than that with glimepiride (17%; P 
0.001). Nausea was reported by 11–19% of the liraglutide-treated subjects versus 3–4% in the
placebo and glimepiride groups. The incidence of nausea declined over time.
CONCLUSIONS — In subjects with type 2 diabetes, once-daily liraglutide induced similar
glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared
with glimepiride, when both had background therapy of metformin.
Diabetes Care 32:84–90, 2009
T
ype 2 diabetes is a progressive dis-
ease characterized by declining
-cell function that, in concert with
insulin resistance, leads to loss of glyce-
miccontrolandeventualdiabetescompli-
cations (1). An oral antidiabetes drug
(OAD) such as metformin is commonly
used in ﬁrst-line pharmacotherapy for
type2diabetes.Sulfonylureasandthiazo-
lidinediones are alternative OAD thera-
pies, but both can elicit weight gain,
whereas sulfonylureas can elicit hypogly-
cemia. Glucagon-like peptide-1 (GLP-1)
has received attention as a therapeutic
agent to provide glycemic control while
avoiding hypoglycemia and weight gain.
GLP-1 is an incretin hormone pro-
duced in the gut that stimulates glucose-
dependent endogenous insulin secretion,
decreases glucagon secretion, slows gas-
tric motility and emptying, and reduces
appetite and food intake (2,3). Further-
more, native GLP-1 stimulates -cell pro-
liferation in animal models and inhibits
apoptosis in vitro, which may increase
-cell mass and function (2). However,
native GLP-1 is not a viable therapeutic
agentbecauseithasashorthalf-lifeof2
min resulting from rapid degradation by
the enzyme dipeptidyl peptidase 4
(DPP-4) and rapid renal elimination (4).
Liraglutide is a human GLP-1 analog
with 97% homology to native GLP-1 (5).
The addition of a fatty acid (palmitate)
side chain and a single amino acid substi-
tution produces self-association of the
molecule that prolongs absorption from
the subcutaneous depot. The fatty acid
sidechainalsopromotesalbuminbinding
thatrendersthemoleculeresistanttodeg-
radation by DPP-4. The resultant plasma
half-life of liraglutide is substantially pro-
longed to 13 h compared with the very
short half-life of native human GLP-1
(6,7).Thepharmacokineticproﬁlemakes
liraglutide suitable for once-daily admin-
istration while achieving 24-h glycemic
control, in contrast to exenatide which
needs to be injected twice daily because it
has a half-life of 2.4 h (5,8,9). Depend-
ing upon dose and duration of treatment,
type 2 diabetic subjects receiving lira-
glutide had mean reductions in A1C of
0.8–1.5%, reductions in fasting blood
glucose of 1.4–3.4 mmol/l, and reduc-
tions in body weight of 1.2–3.0 kg (10–
13). In a recent 52-week monotherapy
study, 51% of subjects treated with 1.8
mg liraglutide reached the American Dia-
betes Association (ADA) target of A1C
7.0% and had weight loss in the ﬁrst 16
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throughout the remainder of the study
(13).
This current trial is part of a phase 3
clinical development program for lira-
glutide. The trial investigates whether
glycemic control (measured by A1C)
achieved by type 2 diabetic subjects us-
ing combination therapy of liraglutide
and metformin is signiﬁcantly better
than that achieved with metformin
monotherapy or at least as good as that
achieved with combination therapy of
metformin and glimepiride.
RESEARCH DESIGN AND
METHODS— Adult subjects with
type 2 diabetes were screened and en-
rolled if they were 18–80 years of age,
had A1C between 7 and 11% (prestudy
OADmonotherapyfor3months)orbe-
tween 7 and 10% (prestudy combination
OAD therapy for 3 months), and had
BMI 40 kg/m
2. Subjects were excluded
if they had used insulin during the previ-
ous 3 months (except short-term treat-
ment). The protocol was approved by
local institutional review boards, and all
subjects provided written informed con-
sent before initiation of any trial-related
activities. The study was conducted in ac-
cordancewiththeDeclarationofHelsinki




multicenter (170 sites), multinational (21
countries) trial, subjects were randomly
assigned (2:2:2:1:2) to receive one of
three once-daily doses of liraglutide (0.6,
1.2, or 1.8 mg/day; Novo Nordisk, Bags-
vaerd,Denmark)injectedsubcutaneously
in combination with metformin, to re-
ceive liraglutide placebo with metformin
monotherapy (placebo group), or to re-
ceive combination therapy with glime-
piride and metformin (4 mg glimepiride
once daily with the ﬁrst meal of the day).
The most relevant position for initiating
treatment with GLP-1 may be after met-
formin failure, but to facilitate recruit-
ment into the trial other monotherapy or
combination treatments were allowed.
Accordingly, the objective of this study
was to compare the efﬁcacy and safety of
liraglutide with both placebo and another
commonly used therapeutic option
(glimepiride) after metformin failure. The
double-dummy design required that sub-
jectsintheliraglutideandplacebogroups
received a glimepiride placebo, whereas
subjects in the glimepiride and placebo
groups received an injection of liraglutide
placebo.
Randomization was performed using
a telephone-based or web-based random-
ization system. Subjects were randomly
assigned to the lowest available random-
izationnumberandstratiﬁedwithrespect
to their previous use of OAD mono-
therapy or combination therapy. Subjects
completing the study could enroll in an
18-month open-label extension period.
Randomizationtotreatmentoccurred
after a 3-week forced metformin titration
period (dose increased up to 2,000 mg/
day: 1,000 mg in the morning and 1,000
mg in the evening) followed by a 3-week
metformin maintenance period. Subjects
taking metformin at enrollment could go
throughamodiﬁedtitrationperiodorad-
vance directly to the metformin mainte-
nance period. After randomization,
subjects underwent a 2- and 3-week titra-
tionperiodforliraglutide(upto0.6,1.2,or
1.8 mg, as per randomization, at 0.6-mg
increases per week) and glimepiride (up to
4 mg, with 1-, 2-, and 4-mg doses at weeks
1, 2, and 3). Glimepiride (active and pla-
cebo) was taken orally once daily in the
morning. Liraglutide (active or placebo)
was injected subcutaneously once daily at
anytimeofthedayintheupperarm,abdo-
men, or thigh using a pen injector device.
Subjects were encouraged to inject lira-
glutide at the same time each day.
Thetitrationperiodwasfollowedbya
23- or 24-week maintenance period dur-
ing which the doses of study drugs were
to be maintained. However, metformin
could be decreased to a minimum of
1,500 mg/day in the case of unacceptable
hypoglycemia or other adverse events but
had to be maintained between 1,500 and
2000 mg/day during the maintenance
period.
The primary outcome measure was
change in A1C at the end of the study.
Secondary end points included changes
in body weight, fasting plasma glucose
(FPG), 7-point plasma glucose proﬁles
(before each meal, 90 min after breakfast,
lunch, and dinner, and at bedtime), and
-cell function based on fasting insulin,
fasting C-peptide, fasting proinsulin-to-
insulin ratio, and the homeostasis model
assessment index of -cell function
(HOMA-B) (15). Laboratory analyses
were performed by a central laboratory
(MDS Pharma Services in Canada,
France, Germany, Singapore, and Swit-
zerland and Laboratories Hildago in Ar-
gentina). A1C was assayed by a method
certiﬁed by the National Glycohemoglo-
bin Standardization Program. Subjects
were provided with MediSense Precision
Xtra/MediSense Optium glucose meters
(Abbott, Maidenhead, U.K.) calibrated
to plasma glucose to determine self-
measured plasma glucose and recorded
values in their diaries. Serum insulin and
C-peptidevaluesweredeterminedusinga
chemiluminescence immunoassay, and
proinsulin was measured in serum using
an enzyme-linked immunosorbent assay.
Safety variables included adverse
events, vital signs, electrocardiogram,
biochemical and hematology measures,
and subject-reported hypoglycemic epi-
sodes (based on symptoms and plasma
glucose 3.1 mmol/l). Minor hypoglyce-
mic episodes were self-treated; major ep-
isodes required third-party assistance.
Statistical analysis
The analyses of efﬁcacy end points were
based on the intent-to-treat population
deﬁned as subjects who were exposed to
at least one dose of trial product and had
one postbaseline measurement of the
parameter. Each end point was analyzed
usinganANCOVAmodelwithtreatment,
country, and previous antidiabetic treat-
ment as ﬁxed effects and baseline as the
covariate. Missing data were imputed as
thelastobservationcarriedforward.Sam-
ple size calculations were based on show-
ing A1C and body weight differences of
0.5 and 3%, respectively, after 6 months
of treatment. The assumed standard de-
viation for A1C and the coefﬁcient of
variance for weight were 1.2 and 3%,
respectively. The combined power (cal-
culated as the product of the marginal
powers for A1C and weight) was at least
85%.
Superiorityornoninferiorityofglyce-
mic control with liraglutide versus com-
parators was concluded if the upper limit
ofthetwo-sided95%CIforthetreatment
difference was 0%; noninferiority was
concluded if it was 0.4%. The propor-
tion of subjects achieving A1C targets
(ADA target 7%; American Association
of Clinical Endocrinologists [AACE] tar-
get6.5%)wascomparedbetweentreat-
ments using a logistic regression model
with treatment and baseline A1C as co-
variates. CIs for secondary end points
were corrected using Dunnett’s test.
Hypoglycemic episodes were analyzed
using a general linear model including
treatment as a ﬁxed effect. Values are ex-
pressed as means  SD unless otherwise
noted. The signiﬁcance level was set at
P  0.05.
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were screened for the study; 571 subjects
failed the screening criteria or withdrew
consent, and the remaining 1,091 sub-
jectswererandomlyassignedtotreatment
after the metformin run-in period. Four
subjects were randomly assigned but
were withdrawn before receiving treat-
ment. Accordingly, the intent-to-treat
and safety (all subjects exposed to study
drug) populations comprised 1,087 sub-
jects and are summarized by treatment
group in Table 1. Baseline characteristics
of the study population appeared to be
balanced across treatment groups (Table
1). The majority (65%) of the randomly
assigned subjects were treated with two
OADs before the study.
Efﬁcacy
At the end of the study, the mean A1C
values for the overall population de-
creased by 0.7  0.1% for the 0.6 mg
liraglutide group and by 1.0  0.1% for
both the 1.2 and 1.8 mg liraglutide
groups and for the glimepiride group and
increased by 0.1  0.1% for the placebo
group (all values means  SEM). The es-
timated treatment differences of all three
liraglutidegroupscomparedwiththepla-
cebo group and the resulting 95% CIs
demonstrated that liraglutide-treated
subjects had superior glycemic control
compared with those in the placebo
group (0.6 mg liraglutide versus placebo
0.8% [95% CI 1.0 to 0.6]; 1.2 mg
liraglutide versus placebo 1.1% [1.3
to0.9];and1.8mgliraglutideversuspla-
cebo 1.1% [1.3 to 0.9]). Analysis of
the estimated treatment difference in A1C
between liraglutide and glimepiride dem-
onstrated that 1.2 and 1.8 mg liraglutide
treatments were noninferior to treatment
with glimepiride (1.2 mg liraglutide versus
glimepiride 0.0% [0.2 to 0.2] and 1.8 mg
liraglutide versus glimepiride 0.0%
[0.2 to 0.2]).
Withintheﬁrst12weeksofthestudy,
mean A1C values for the overall popula-
tion decreased from baseline for all lira-
glutide treatment groups and for the
glimepiride group whereas a slight in-
crease was observed in the placebo group
(Fig. 1A). The A1C proﬁles for subjects
stratiﬁed by prestudy OAD therapy
(monotherapy or combination therapy)
were similar in appearance to those of the
overall population (Fig. 1B and C). How-
ever, the baseline and end-of-study mean
A1C values in the monotherapy group
were slightly less than those in the com-
bination therapy group, and the resulting
change-from-baselinedecreasesappeared
to be slightly greater in the monotherapy
group than in the combination therapy
group (Fig. 1D).
The percentages of subjects reaching
the ADA and AACE A1C goals were dose-
dependent for liraglutide treatment in
overall subjects and in subjects with pre-
study OAD monotherapy or combination
therapy (Fig. 1E and F). For the overall
population, a logistic regression analysis
demonstrated that a signiﬁcantly greater
percentage of subjects in all of the lira-
glutide groups achieved the ADA and
AACE A1C goals than subjects in the re-
spective placebo groups (P  0.02 for all
comparisons of liraglutide to placebo for
both A1C goals). The percentages of sub-
jects in the 1.2 and 1.8 mg liraglutide
treatmentgroupsachievingtheADAand
AACE A1C goals were comparable to
the percentage achieving goals in the
glimepiridegroup.However,fortheover-
all population, the ADA target was
achieved by signiﬁcantly more subjects in
Table 1—Characteristics of enrolled population and subject disposition
Once-daily liraglutide Once-daily 4 mg
glimepiride Placebo 0.6 mg 1.2 mg 1.8 mg
Sex: male/female (%) 62/38 54/46 59/41 57/43 60/40
Age (years) 56  11 57  95 7  95 7  95 6  9
Race: C/B/A/O (%) 84/2/13/2 88/4/8/1 88/2/7/2 89/2/9/1 88/3/7/3
BMI (kg/m
2) 30.5  4.8 31.1  4.8 30.9  4.6 31.2  4.6 31.6  4.4
Duration of diabetes (years) 7  57  58  58  58  6
Prestudy OAD treatment
Monotherapy 81 (34) 91 (38) 83 (34) 89 (37) 41 (34)
Metformin 70 (86) 78 (86) 72 (87) 82 (92) 38 (93)
Sulfonylurea 9 (11) 12 (13) 11 (13) 7 (8) 3 (7)
Repaglinide 2 (3) 1 (1) 0 0 0
Combination therapy 161 (67) 150 (62) 159 (66) 155 (63) 81 (66)
A1C (%) 8.4  0.9 8.3  1.0 8.4  1.0 8.4  1.0 8.4  1.1
FPG (mmol/l) 10.2  2.4 9.9  2.3 10.1  2.3 10.0  2.6 10.0  2.3
SBP (mmHg) 131  14 132  14 131  14 132  16 135  16
DBP (mmHg) 80  88 0  10 79  88 0  88 1  9
Randomized 242 241 242 244 122
Exposed (ITT and safety populations) 242 240 242 242 121
Completers 208 (86) 197 (82) 191 (79) 210 (86) 74 (61)
Withdrawals 34 (14) 44 (18) 51 (21) 34 (14) 48 (39)
Adverse events 11 (5) 23 (10) 29 (12) 8 (3) 2 (2)
Nausea/vomiting/diarrhea 3 (1) 13 (5) 20 (8) 0 0
Ineffective therapy 19 (8) 8 (3) 13 (5) 9 (4) 29 (24)
Noncompliance 2 (1) 4 (2) 4 (2) 5 (2) 4 (3)




86 DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009the 1.8 mg liraglutide group than in the
1.2 mg liraglutide group (42.4 vs. 35.3%,
P  0.0265).
FPG values decreased within the 2
weeks of randomization in the liraglutide
groups and in the glimepiride group and
increased in the placebo group, remain-
ing relatively stable thereafter. At the end
of the study, FPG values were 9.1  2.5,
Figure 1— A1C proﬁles for the overall study population (A), for subjects with prestudy oral monotherapy (B), and for subjects with prestudy oral
combination therapy (C). D: Change in A1C for the overall study population and for subjects treated by prestudy monotherapy or combination
therapy.ErrorbarsinA,B,C,andDrepresent2SEM.PercentagesofsubjectsachievingADA(E)andAACE(F)A1Cgoalsattheendofthestudy
weredeterminedusingalogisticregressionanalysis.SymbolsforA–C:pinkboxes,0.6mg/dayliraglutide;circles,1.2mg/dayliraglutide;diamonds,
1.8 mg/day liraglutide; triangles, 4 mg/day glimepiride; gray boxes, placebo. QD, every day.
Nauck and Associates
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10.7  3.2 mmol/l in the 0.6 mg lira-
glutide, 1.2 mg liraglutide, 1.8 mg lira-
glutide, glimepiride, and placebo groups,
respectively. The decreases in FPG from
baseline for all of the liraglutide groups
(1.1, 1.6, and 1.7 mmol/l for 0.6,
1.2, and 1.8 mg liraglutide groups, re-
spectively) were signiﬁcantly greater than
the increase observed for the placebo
group (0.4 mmol/l, P  0.0001) but were
similar to the decrease observed for the
glimepiride group (1.3 mmol/l).
Mean postprandial glucose values
(mean of three meals), from self-
monitored 7-point plasma glucose mea-
surements at the end of the study,
decreased from baseline in all treatment
groups (1.7 mmol/l for 0.6 mg lira-
glutide, 2.3 mmol/l for 1.2 mg lira-
glutide, and 2.6 mmol/l for 1.8 mg
liraglutide, 2.5 mmol/l for glimepiride,
and 0.6 mmol/l for placebo; P  0.001
for comparisons of all liraglutide groups
to placebo; the decreases in the 1.2 and
1.8 mg liraglutide groups were compara-
ble to those with glimepiride). The blood
glucose values 90 min after breakfast,
lunch, and dinner for the 1.8 mg lira-
glutide group at week 26 appeared to be
similar across the three meals (9.9, 9.5,
and 9.7 mmol/l, respectively) and ap-
peared to be similar to the corresponding
blood glucose values observed in the
glimepiride group (10.0, 9.2, and 9.7
mmol/l, respectively) and slightly less
than the corresponding values in the pla-
cebogroup(11.0,10.7,and10.9mmol/l,
respectively).
Weight loss was dose dependent in
the liraglutide treatment groups (1.8 
0.2, 2.6  0.2, and 2.8  0.2 kg for 0.6,
1.2, and 1.8 mg liraglutide groups, re-
spectively) and was signiﬁcantly different
(P  0.0001) from the weight gain in the
glimepiride group (1.0  0.2 kg). The
weight losses in the 1.2 and 1.8 mg lira-
glutide groups were also signiﬁcantly
greater (P  0.01) than the weight loss in
the placebo group (1.5  0.3 kg). The
great majority of subjects either did not
report nausea or reported nausea for 7
days during the ﬁrst 8 weeks of treatment
and did not report nausea or reported
nausea for 7 days in weeks 8–26 of
treatment (86–93% in the liraglutide
groups and 98–99% in the placebo and
glimepiride groups). As such, the occur-
rence of nausea did not appear to account
for the weight loss.
The decreases in the proinsulin-to-
insulinratiofrombaseline(baselineof0.4
across all groups) for the three liraglutide
groups (decrease by 0.1) were compara-
ble to those in the glimepiride group and
were signiﬁcantly different (P  0.0001)
than those in the placebo group, which
increased from baseline by 0.1. No signif-
icant differences in the change-from-
baseline fasting insulin and fasting
C-peptide values were observed between
the liraglutide treatment groups com-
pared with either the glimepiride or pla-
cebo groups. The liraglutide treatment
groups had improvements in HOMA-B of
63, 70, and 71% for the 0.6, 1.2, and 1.8
mg liraglutide groups from baseline val-
ues of 40, 47, and 43%, respectively. The
glimepiride group had a similar improve-
ment in the mean HOMA-B value to 68%
from a baseline value of 43%. No im-
provement in HOMA-B was observed in
the placebo group; baseline and end-of-
study values were 45 and 43%, respec-
tively. No signiﬁcant differences were
observed between treatments for the ho-
meostasis model assessment index of in-
sulin resistance.
The1.2and1.8mgliraglutidegroups
had signiﬁcant reductions in systolic
blood pressure (SBP) of 2–3 mmHg com-
pared with the increase in SBP of 0.4
mmHg observed in the glimepiride group
(treatment difference compared with
glimepiride: 1.2 mg liraglutide, 3.2
mmHg, P  0.0128; 1.8 mg liraglutide,
2.7mmHg,P0.0467).Thedecreases
in SBP in the 0.6 mg liraglutide and pla-
cebo groups were 0.6 and 1.8 mmHg, re-
spectively. On the basis of the SBP and
weightproﬁlesovertime,thereductionin
SBP may not be fully explained by the
reductioninbodyweight.Diastolicblood
pressure did not appear to change from
baseline for any groups.
Safety
Gastrointestinal disorders (nausea, vom-
iting, and diarrhea) were the most fre-
quently reported adverse events in the
liraglutidegroupsandwerereporteddur-
ing the course of the study by 35, 40, and
44% of the subjects in the 0.6, 1.2, and
1.8 mg liraglutide groups, respectively,
and by 17% in the placebo and
glimepiridegroups.Overall,nauseaalone
was experienced by 11, 16, and 19% of
the subjects in the 0.6, 1.2, and 1.8 mg
liraglutide groups, respectively; however,
10% of the subjects were experiencing
nauseaonaweeklybasisbyweek4.Vom-
iting was experienced by 5–7% in the
liraglutide groups and by 1% in the pla-
cebo and glimepiride groups; diarrhea
was experienced by 10, 8, and 15% in the
0.6, 1.2, and 1.8 mg liraglutide groups,
respectively, and by 4% in the placebo
and glimepiride groups.
The percentages of subjects with-
drawn because of adverse events were
generally greater in the liraglutide groups
than in the glimepiride or placebo groups
(Table 1). Nausea, vomiting, and/or diar-
rhea were the gastrointestinal events that
led to the withdrawal of 36 liraglutide-
treated subjects (5% of all liraglutide-
treated subjects) in a dose-dependent
manner (Table 1). Most of these adverse
event withdrawals caused by gastrointes-
tinal disorders occurred during the ﬁrst
month of therapy. One subject in the 1.2
mg liraglutide group and one in the
glimepiride group were withdrawn for
acute pancreatitis during the study. Nei-
ther subject had a prior history of pancre-
atitis,andbothsubjectswerehospitalized
for 7 days and subsequently recovered.
One death (cardiorespiratory arrest) was
reported during the trial and occurred
during the metformin run-in period, be-
fore randomization to treatment. A sec-
ond subject had liver cirrhosis and
hepatocellular carcinoma during the trial
and died after the trial had completed.
Both deaths were unrelated to liraglutide
treatment.
In general, minor hypoglycemia oc-
curred at low incidence (3% of subjects
in the placebo and liraglutide groups and
17% in the glimepiride group), resulting
in a relatively low rate of reported minor
hypoglycemia (0.03–0.14 events/year for
the placebo and liraglutide groups and
1.23 events/year for the glimepiride
group) that was signiﬁcantly less for all
three liraglutide groups than for the
glimepiride group (P  0.001). No major
hypoglycemic events were reported.
No clinically relevant between-
treatment differences were observed in
physicalexaminationﬁndings,laboratory
analyses (hematology and biochemistry
analyses), electrocardiogram, or ophthal-
moscopy. No signiﬁcant differences in
calcitonin laboratory values were found
between the liraglutide groups and either
the placebo or glimepiride group. Slight
increasesinpulseratewereobservedinall
treatment groups (2–3 bpm in the lira-
glutide groups and 1 bpm in the glime-
pirideandplacebogroups).Theincreases
in pulse in the 0.6 and 1.2 mg liraglutide
groupsweresigniﬁcantlygreaterthanthat
in the glimepiride group (P  0.012 and
P  0.024, respectively).
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onstrated that treatment with liraglutide
once daily (0.6, 1.2, or 1.8 mg) in combi-
nation with metformin provided im-
provement in A1C superior to that of
metformin monotherapy (placebo group)
and noninferior to that of combination
therapy of glimepiride and metformin
(glimepiride group). The improvements
in A1C for liraglutide-treated subjects re-
ceivingprestudyOADmonotherapywere
greater (decrease of 1.3% for 1.8 mg lira-
glutide) than the improvements for sub-
jects with prestudy oral combination
therapy (decrease of 0.8%, 1.8 mg lira-
glutide, signiﬁcance not tested). The
monotherapy group probably had greater
improvement because they added lira-
glutide onto a monotherapy treatment
whereas liraglutide was substituted for
one of the prestudy oral therapies (other
than metformin) in the subjects receiving
prestudy combination therapy. The ﬁnd-
ingsofthecurrentstudydemonstratethat
liraglutideisaneffectivetreatmentoption
for combination therapy with metformin
when subjects are not achieving glycemic
control with metformin therapy alone.
The decrease in A1C observed in the
prestudy monotherapy group conﬁrms
the A1C decrease observed (1.45%) in
subjects treated with liraglutide mono-
therapy in a prior 14-week study (10).
Another recent liraglutide phase 3 study
demonstrated that a subgroup of subjects
previously treated with diet and exercise
and then treated with 1.8 mg liraglutide
monotherapyhadameanA1Cdecreaseof
1.60% that was sustained over the 52-
week trial period. In this subgroup, the
decrease in A1C was signiﬁcantly greater
than the decrease achieved in the corre-
sponding glimepiride control group in
the same study (0.88%; P  0.05) (13).
A1C decreases by subjects previously
treated with metformin monotherapy
have also been observed with the GLP-1
agonist exenatide (decrease of 0.8%) or
with the DPP-4 inhibitor sitagliptin (de-
crease of 0.65%) in populations of pa-
tients with type 2 diabetes inadequately
controlled with previous metformin
monotherapy (16,17).
The percentages of liraglutide-treated
subjects achieving A1C targets are reﬂec-
tive of the decreases in A1C values for the
overall population and for the subgroups
stratiﬁed by prior OAD therapy. Greater
percentages of subjects receiving pre-
study monotherapy achieved the target
compared with their respective counter-
parts receiving prestudy combination
therapy(66and39%,respectively,for1.8
mg liraglutide) (compare Fig. 1E and F).
Thisﬁndingprobablyresultsfromthead-
dition of liraglutide as a second therapeu-
ticagentinsubjectswhosetype2diabetes
may not be as advanced as that is those
subjects entering the study with prestudy
combination therapy.
In this study, liraglutide provided
24-hglycemiccontrolasdemonstratedby
the similar postprandial blood glucose
values after each of the three meals. The
postprandial values of the 1.8 mg lira-
glutide group also appeared to be similar
to those of the glimepiride group and less
than those of the placebo group.
Nausea, vomiting, and diarrhea are
known side effects of GLP-1 receptor
agonists. The incidence of gastrointesti-
nal effects in this study increased dose
dependently during the ﬁrst 2 weeks of
liraglutide treatment but decreased
thereafter. In studies with treatment of
exenatide,subjectsreportednauseathat
also decreased in incidence over time
(16,18,19). The dose dependence and
transient nature of gastrointestinal side
effectsinthecurrenttrialsuggestthatin
clinical practice liraglutide should be ti-
trated from a starting dose of 0.6 mg/
day up to 1.2 mg/day and then up to 1.8
mg/day. Apart from the gastrointestinal
sideeffects,liraglutidetreatmentwasgener-
ally well tolerated and had a low incidence
of hypoglycemia that was comparable to
that of the placebo group (metformin
monotherapy). A reduction in SBP was also
observed in the 1.2 and 1.8 mg liraglutide
groups (2–3 mmHg) within 2 weeks of
treatment and could not be explained en-
tirely by weight loss that occurred over a
greater time frame.
Liraglutidewasshowntobesimilarto
glimepiride in improving HOMA-B val-
uesinthecurrentstudy.Improvementsin
-cell function with liraglutide treatment
have been observed in several other stud-
ies with liraglutide (10,20,21). Further-
more, liraglutide has been shown to
increase-cellmassinanimalmodelsand
decrease-cellapoptosisinvitro(22,23).
Such improvements in -cell function
havethepotentialtodelaytype2diabetes
progression.
The liraglutide-treated subjects gener-
ally had improvements in glycemic param-
eters (decreases in A1C, FPG, and
postprandial glucose from baseline) similar
to those of glimepiride-treated subjects.
However, the glimepiride group had a sig-
niﬁcant increase in weight compared with
the liraglutide groups and experienced a
signiﬁcantly greater rate of hypoglycemia.
Thus, addition of once-daily liraglutide to
metformin monotherapy is a viable treat-
ment option if weight gain and hypoglyce-
mia are a concern.
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